Arun V Ravindran

Summary

Affiliation: Centre for Addiction and Mental Health
Country: Canada

Publications

  1. ncbi request reprint Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women
    Meir Steiner
    Department of Psychiatry and Behavioral Neurosciences, McMaster University and Women s Health Concerns Clinic, St Joseph s Healthcare, Hamilton, Ontario, Canada
    J Clin Psychiatry 69:991-8. 2008
  2. ncbi request reprint Lamotrigine in the treatment of recurrent brief depression
    Lakshmi N Ravindran
    University of Toronto, Department of Psychiatry, University Health Network, Toronto, Ontario Canada
    Int Clin Psychopharmacol 22:121-3. 2007
  3. ncbi request reprint Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series
    L N Ravindran
    Department of Psychiatry, University of Toronto, Toronto, Canada
    Arch Womens Ment Health 10:125-7. 2007
  4. ncbi request reprint Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders
    Arun V Ravindran
    University of Toronto, Mood and Anxiety Disorders Program, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Expert Opin Pharmacother 8:1693-710. 2007
  5. doi request reprint Intravenous anti-obsessive agents: a review
    L N Ravindran
    Department of Psychiatry, VA San Diego Health Care System, San Diego, California, USA
    J Psychopharmacol 24:287-96. 2010
  6. ncbi request reprint Obsessive-compulsive spectrum disorders: a review of the evidence-based treatments
    Arun V Ravindran
    University of Toronto, Ontario, Canada
    Can J Psychiatry 54:331-43. 2009
  7. doi request reprint Toward a functional neuroanatomy of dysthymia: a functional magnetic resonance imaging study
    Arun V Ravindran
    University of Toronto, Mood and Anxiety Disorders Program, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, Canada M5T 1R8
    J Affect Disord 119:9-15. 2009
  8. doi request reprint Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments
    Arun V Ravindran
    University of Toronto, Canada
    J Affect Disord 117:S54-64. 2009
  9. ncbi request reprint Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial
    Arun V Ravindran
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychiatry 69:87-94. 2008
  10. ncbi request reprint Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder
    Arun Ravindran
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Clin Pharmacokinet 43:733-40. 2004

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women
    Meir Steiner
    Department of Psychiatry and Behavioral Neurosciences, McMaster University and Women s Health Concerns Clinic, St Joseph s Healthcare, Hamilton, Ontario, Canada
    J Clin Psychiatry 69:991-8. 2008
    ..To evaluate the efficacy and safety of intermittent, luteal phase-only administration of paroxetine (10 mg and 20 mg) in the treatment of premenstrual dysphoric disorder (PMDD)...
  2. ncbi request reprint Lamotrigine in the treatment of recurrent brief depression
    Lakshmi N Ravindran
    University of Toronto, Department of Psychiatry, University Health Network, Toronto, Ontario Canada
    Int Clin Psychopharmacol 22:121-3. 2007
    ..We report on two patients with recurrent brief depression, nonresponsive to selective serotonin reuptake inhibitors and venlafaxine, and who responded to therapeutic doses of lamotrigine...
  3. ncbi request reprint Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series
    L N Ravindran
    Department of Psychiatry, University of Toronto, Toronto, Canada
    Arch Womens Ment Health 10:125-7. 2007
    ..Primary efficacy variables were the premenstrual tension scale (PMTS-O) and the clinical global impression of improvement (CGI). Treatment was associated with significant improvement in PMDD symptoms (p < 0.001)...
  4. ncbi request reprint Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders
    Arun V Ravindran
    University of Toronto, Mood and Anxiety Disorders Program, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Expert Opin Pharmacother 8:1693-710. 2007
    ..The published evidence is summarized, with recommendations and suggestions for its use...
  5. doi request reprint Intravenous anti-obsessive agents: a review
    L N Ravindran
    Department of Psychiatry, VA San Diego Health Care System, San Diego, California, USA
    J Psychopharmacol 24:287-96. 2010
    ..Preliminary evidence suggests subgroups of patients with severe treatment-refractory OCD may benefit from i.v. anti-obsessive agents, CMI and citalopram. Larger, controlled trials are needed for more definitive conclusions...
  6. ncbi request reprint Obsessive-compulsive spectrum disorders: a review of the evidence-based treatments
    Arun V Ravindran
    University of Toronto, Ontario, Canada
    Can J Psychiatry 54:331-43. 2009
    ....
  7. doi request reprint Toward a functional neuroanatomy of dysthymia: a functional magnetic resonance imaging study
    Arun V Ravindran
    University of Toronto, Mood and Anxiety Disorders Program, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, Canada M5T 1R8
    J Affect Disord 119:9-15. 2009
    ..Recent studies have confirmed the neurobiological and treatment response overlap of dysthymia with major depression. There are no previous published studies of functional magnetic resonance imaging (fMRI) in dysthymia...
  8. doi request reprint Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments
    Arun V Ravindran
    University of Toronto, Canada
    J Affect Disord 117:S54-64. 2009
    ..There is widespread interest in complementary and alternative medicine (CAM) therapies in the treatment of major depressive disorder (MDD)...
  9. ncbi request reprint Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial
    Arun V Ravindran
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychiatry 69:87-94. 2008
    ..To evaluate the efficacy, safety, and tolerability of adjunctive osmotic-release oral system (OROS) methylphenidate in outpatients with major depressive disorder (MDD) receiving a stable oral antidepressant regimen...
  10. ncbi request reprint Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder
    Arun Ravindran
    Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Clin Pharmacokinet 43:733-40. 2004
    ..The aims of this study were to determine the effect of repeated doses of oral risperidone on the pharmacokinetics of valproate in subjects stabilised on divalproex sodium and to document the safety of this combination...
  11. doi request reprint Quetiapine: novel uses in the treatment of depressive and anxiety disorders
    Arun V Ravindran
    University of Toronto, Ontario, Toronto, Canada
    Expert Opin Investig Drugs 19:1187-204. 2010
    ..However, it is often used (off-label) to treat other depressive disorders and anxiety disorders in children and adults...
  12. doi request reprint Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication
    Sagar V Parikh
    University of Toronto, Canada
    J Affect Disord 117:S15-25. 2009
    ..This article, one of five in the series, reviews new studies of psychotherapy in the acute and maintenance phase of MDD, including computer-based and telephone-delivered psychotherapy...
  13. doi request reprint Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study
    Arun V Ravindran
    Centre for Addiction and Mental Health, 100 Stokes St, Toronto, ON M6J 1H4, Canada
    Asian J Psychiatr 6:157-61. 2013
    ..04). Reporting of multiple side effects was also higher with paroxetine than with placebo (p=0.02). Paroxetine is more effective than placebo in improving symptoms and quality of life in dysthymia, and is generally tolerable...
  14. doi request reprint Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies
    Sidney H Kennedy
    University of Toronto, Canada
    J Affect Disord 117:S44-53. 2009
    ..There is renewed interest in refined approaches to brain stimulation, particularly for treatment resistant major depressive disorder (MDD)...
  15. ncbi request reprint Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder
    Basil G Bereza
    Student, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario
    Can J Psychiatry 57:470-8. 2012
    ..However, such analysis provides an additional resource for clinicians to make more effective treatment decisions for individual patients with GAD...
  16. ncbi request reprint Yoga in the treatment of mood and anxiety disorders: A review
    Tricia L da Silva
    Centre for Addiction and Mental Health, 250 College St, Toronto, Ont, Canada M5T 1R8
    Asian J Psychiatr 2:6-16. 2009
    ..Despite research interest, there are few recent reviews of the evidence of the benefit of yoga in these conditions...
  17. doi request reprint Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: A systematic review
    Arun V Ravindran
    Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario, Canada M5T 1R8 Division of Mood and Anxiety Disorders, Centre for Addiction and Mental Health, 100 Stokes Street, Toronto, Ontario, Canada M6J 1H4 Electronic address
    J Affect Disord 150:707-19. 2013
    ..The benefits and risks of such combination strategies have not been fully evaluated. This paper evaluates the risk-benefit profile of CAM augmentation to antidepressants in affective conditions...
  18. doi request reprint Obesity comorbidity in unipolar major depressive disorder: refining the core phenotype
    Robert D Levitan
    Department of Psychiatry, University of Toronto, Canada
    J Clin Psychiatry 73:1119-24. 2012
    ....
  19. ncbi request reprint Stress, coping, uplifts, and quality of life in subtypes of depression: a conceptual frame and emerging data
    Arun V Ravindran
    Department of Psychiatry, Royal Ottawa Hospital, Department of Psychology, Ottawa, Ontario, Canada
    J Affect Disord 71:121-30. 2002
    ....
  20. ncbi request reprint Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study
    Kirsten Behnke
    Falkoner Allé, Frederiksberg, The Netherlands
    J Clin Psychopharmacol 23:358-64. 2003
    ..The orally disintegrating tablet formulation of mirtazapine used in this study is known to enhance the convenience and compliance by the patient...
  21. ncbi request reprint Effect of valproate on plasma levels of interleukin-6 in healthy male humans
    I Shin Shiah
    Department of Psychiatry, Tri Service General Hospital, National Defense Medical Center, Taipei, Taiwan
    Int Clin Psychopharmacol 20:295-8. 2005
    ....
  22. pmc Effects of short-term administration of valproate on serotonin-1A and dopamine receptor function in healthy human subjects
    Nicholas J Delva
    Departments of Psychiatry and Physiology, Queen s University, Providence Continuing Care Centre, Mental Health Services, Kingston, ON
    J Psychiatry Neurosci 27:429-37. 2002
    ..To examine the effects of short-term valproate treatment on human brain serotonin and dopamine function by means of challenge tests with ipsapirone, a partial agonist at 5-HT1A receptors, and apomorphine, a dopamine receptor agonist...
  23. ncbi request reprint Does fluoxetine influence major depression by modifying five-factor personality traits?
    Lisheng Du
    Institute of Mental Health Research at Royal Ottawa Hospital and University of Ottawa, 1145 Carling Ave, Ottawa, Ontario K1Z 7K4, Canada
    J Affect Disord 71:235-41. 2002
    ....
  24. ncbi request reprint Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study
    Richard Bergeron
    McGill University, Montreal, Quebec, Canada
    J Clin Psychopharmacol 22:148-54. 2002
    ..significant efficacy in the treatment of outpatients with moderate to severe OCD with the subjects treated with sertraline showing a greater likelihood of remission as well as an earlier improvement on some but not all efficacy measures..